BUY Park Medi World Limited — Pankaj Randad
byPankaj RandadHorizon: NA (inferred Swing (≤2wk))3 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Healthcare stock Park Medi World inches close to record high ahead of the Q1 results 2026
NewsLivemint·3 Aug · today
Healthcare stock Park Medi World inches close to record high after the Q1 results 2026
NewsLivemint·3 Aug · today
Park Medi World Ltd announced Q1 FY'27 unaudited results with a 19% YoY revenue growth, 20% EBITDA growth, and 35% Net Profit growth. The company also plans to add 1,490 beds in 2026.
BSE · Company Update·3 Aug · today
Park Medi World Ltd has acquired Mehar Hospital Zirakpur. This strategic acquisition is expected to expand the company's healthcare footprint and service offerings.
BSE · Company Update·3 Aug · today
Park Medi World Limited has executed a definitive agreement to acquire Mehar Hospital - Zirakpur for INR 107 Crores. This acquisition is expected to deepen the company's presence in Punjab and is proj
NSE · Acquisition·3 Aug · today
Park Medi World Limited announced the outcome of its Board Meeting held on August 03, 2026. Key agenda items included approval of unaudited financial results for Q1 FY27 and the acquisition of Mehar H
NSE · Outcome of Board Meeting·3 Aug · today
Park Medi World Ltd announced the outcome of its Board Meeting held on August 03, 2026. The board considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter en
BSE · Board Meeting·3 Aug · today
Company provided an update on the acquisition of The Medicity Hospital, Rudrapur.
BSE · Company Update·31 Jul · 2d ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.